Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Navidea Biopharma (NAVB) Reports Q2 Loss of $0.11, Revenues Beat
August 13, 2020 4:32 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.11), versus ($0.24) reported last year. Revenue for the quarter came in at $271 thousand versus the consensus estimate of $156 thousand.
The past four months have been truly momentous for the company. The successful second interim look... More
